These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 19848437)

  • 21. Memantine for dementia.
    Areosa SA; Sherriff F
    Cochrane Database Syst Rev; 2003; (1):CD003154. PubMed ID: 12535459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized study.
    Chen CC; Wei ST; Tsaia SC; Chen XX; Cho DY
    Br J Neurosurg; 2013 Dec; 27(6):803-7. PubMed ID: 23656173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Galantamine for vascular cognitive impairment.
    Craig D; Birks J
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD004746. PubMed ID: 16437493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease.
    Ruether E; Husmann R; Kinzler E; Diabl E; Klingler D; Spatt J; Ritter R; Schmidt R; Taneri Z; Winterer W; Koper D; Kasper S; Rainer M; Moessler H
    Int Clin Psychopharmacol; 2001 Sep; 16(5):253-63. PubMed ID: 11552768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Donepezil for dementia due to Alzheimer's disease.
    Birks J; Harvey RJ
    Cochrane Database Syst Rev; 2006 Jan; (1):CD001190. PubMed ID: 16437430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Donepezil for dementia due to Alzheimer's disease.
    Birks JS; Harvey R
    Cochrane Database Syst Rev; 2003; (3):CD001190. PubMed ID: 12917900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vinpocetine for cognitive impairment and dementia.
    Szatmari SZ; Whitehouse PJ
    Cochrane Database Syst Rev; 2003; 2003(1):CD003119. PubMed ID: 12535455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer's Disease.
    Alvarez XA; Alvarez I; Martinez A; Romero I; Benito C; Suarez I; Mourente S; Fantini M; Figueroa J; Aleixandre M; Linares C; Muresanu D; Winter S; Moessler H
    Int J Neuropsychopharmacol; 2020 Dec; 23(9):581-586. PubMed ID: 32640027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rivastigmine for vascular cognitive impairment.
    Birks J; McGuinness B; Craig D
    Cochrane Database Syst Rev; 2013 May; (5):CD004744. PubMed ID: 23728651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy.
    Rüther E; Ritter R; Apecechea M; Freytag S; Gmeinbauer R; Windisch M
    J Neural Transm (Vienna); 2000; 107(7):815-29. PubMed ID: 11005546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
    Small G; Erkinjuntti T; Kurz A; Lilienfeld S
    CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrolysin and early neurorehabilitation in patients with acute ischemic stroke: a prospective, randomized, placebo-controlled clinical study.
    Stan A; Birle C; Blesneag A; Iancu M
    J Med Life; 2017; 10(4):216-222. PubMed ID: 29362596
    [No Abstract]   [Full Text] [Related]  

  • 33. Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials.
    Passmore AP; Bayer AJ; Steinhagen-Thiessen E
    J Neurol Sci; 2005 Mar; 229-230():141-6. PubMed ID: 15760632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
    Kavirajan H; Schneider LS
    Lancet Neurol; 2007 Sep; 6(9):782-92. PubMed ID: 17689146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrolysin Asian Pacific trial in acute brain injury and neurorecovery: design and methods.
    Poon W; Vos P; Muresanu D; Vester J; von Wild K; Hömberg V; Wang E; Lee TM; Matula C
    J Neurotrauma; 2015 Apr; 32(8):571-80. PubMed ID: 25222349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.
    Alvarez XA; Cacabelos R; Laredo M; Couceiro V; Sampedro C; Varela M; Corzo L; Fernandez-Novoa L; Vargas M; Aleixandre M; Linares C; Granizo E; Muresanu D; Moessler H
    Eur J Neurol; 2006 Jan; 13(1):43-54. PubMed ID: 16420392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Memantine for dementia.
    Areosa Sastre A; McShane R; Sherriff F
    Cochrane Database Syst Rev; 2004 Oct; (4):CD003154. PubMed ID: 15495043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Neuropsychological evaluation of long-term therapy of Alzheimer's disease using different cerebrolysin dosages].
    Roshchina IF; Gavrilova SI; Zharikov GA; Kalyn IaB; Kolykhalov IV; Selezneva ND
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(1):52-5. PubMed ID: 15704485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nimodipine for primary degenerative, mixed and vascular dementia.
    López-Arrieta ; Birks J
    Cochrane Database Syst Rev; 2001; (1):CD000147. PubMed ID: 11279679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Experience with using high doses of cerebrolysin in vascular dementia].
    Iakhno NN; Damulin IV; Zakharov VV; Levin OS; Elkin MN
    Ter Arkh; 1996; 68(10):65-9. PubMed ID: 9026950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.